Structured Product Formula For Ramipril (9eac2e75 3766 4394 A435 547cdc840b42 01)
Ramipril Capsule
Product Images NDC 68382-147
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ramipril (NDC 68382-147). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (9eac2e75 3766 4394 A435 547cdc840b42 02)
The text describes a graph showing Kaplan-Meier Estimates of the Composite Outcome of Myocardial Infarction, Stroke, or Death from Cardiovascular Causes in the Ramipril Group and the Placebo Group. The x-axis indicates the Days of Follow-up, while the y-axis is not clear from the text. The graph displays two lines representing the Ramipril Group and the Placebo Group. The Placebo group has a higher rate of the composite outcome than the Ramipril group with a statistical significance of p=0.0001.*
Figure 2 (9eac2e75 3766 4394 A435 547cdc840b42 03)
This is a figure with some tabular data, showing the effect of treatment with Ramipril on the composite outcome of myocardial infarction, stroke, or death from cardiovascular causes. The table includes various subgroups such as those with cardiovascular and cerebrovascular disease, hypertension, diabetes, and age categories. The incidence of the composite outcome is shown for the Ramipril group and the Placebo group, with the number of patients in each group. The figure also includes a graph with confidence intervals. No further context or information is available.*
Ramipril Capsules, 1.25 mg (9eac2e75 3766 4394 A435 547cdc840b42 04)
This is a description of a medication labeled as Ramipril capsules with a strength of 0.25mg. It is distributed by Zydus Pharmaceuticals USA Inc. It comes in a bottle of 30 capsules, and should be stored at a temperature between 20-25°C (66-77°F). It also includes a code number of GUIDRUGI1486.*
Ramipril Capsules, 2.5 mg (9eac2e75 3766 4394 A435 547cdc840b42 05)
Ramipril Capsules, 5 mg (9eac2e75 3766 4394 A435 547cdc840b42 06)
Ramipril is a drug that comes in capsules and is stored at room temperature. The packaging contains dosage instructions and prescribing information. The drug should be kept out of reach of children. The output also lists the drug code as GUIDRUGI1486 and the manufacturer as 71s Pharmaceuticals.*
Ramipril Capsules, 10 mg (9eac2e75 3766 4394 A435 547cdc840b42 07)
This is a label for Ramipril Capsules, USP, containing 10mg per capsule. The usual dosage information is provided in the package insert. It should be stored at room temperature and kept in a child-resistant container. The drug is manufactured in India by Cadla Healthcare Ltd and distributed by Zydus Pharmaceuticals in the USA. The label includes a warning to keep the drug out of reach of children.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
